We can’t show the full text here under this license. Use the link below to read it at the source.
Hyperkalemia and maintenance of renin–angiotensin system inhibitor therapy after initiating SGLT-2 or DPP-4 inhibitors
High potassium levels and continuing blood pressure medicine after starting SGLT-2 or DPP-4 diabetes drugs
AI simplified
Abstract
In a study of 29,849 adults with type 2 diabetes, were associated with a lower rate of compared to DPP-4 inhibitors.
- SGLT-2 inhibitors were linked to a 23% lower rate of hyperkalemia (hazard ratio 0.77) compared to DPP-4 inhibitors.
- This reduction in hyperkalemia included a 24% lower rate of mild hyperkalemia and a 47% lower rate of moderate to severe hyperkalemia.
- Seven percent of RAS inhibitor users discontinued therapy, but the initiation of SGLT-2 inhibitors did not influence the rate of RAS inhibitor discontinuation.
- About one-third of participants in both groups discontinued treatment within one year.
- Results were consistent across various patient subgroups, including sex and cardiovascular disease status.
AI simplified
Key numbers
0.77
Lower Rate of
Adjusted hazard ratio for any events.
7%
Incidence of RASi Discontinuation
Percentage of participants who discontinued RASi therapy.
3.4%
1-Year Absolute Risk of
Absolute risk of in SGLT-2i users after one year.